Product title
Vendor
$19.99 | $24.99
Product title
Vendor
$19.99 | $24.99
Product title
Vendor
$19.99 | $24.99
Product title
Vendor
$19.99 | $24.99
Targeted Mast Cell Tumor Treatment for Dogs
Product Description
PALLADIA® Tablets are an FDA-approved oral cancer treatment for dogs with recurrent Patnaik grade II or III cutaneous mast cell tumors. This targeted tyrosine kinase inhibitor works by blocking tumor cell growth and reducing blood supply to tumors. Designed for veterinary-prescribed use, it offers a clinically proven systemic treatment option when surgery alone is not sufficient.
Benefits
- Targeted Therapy: Selectively inhibits receptor tyrosine kinases involved in mast cell tumor growth and progression.
- Dual Action Mechanism: Works by killing tumor cells and reducing tumor blood vessel formation.
- Clinically Proven Response: Demonstrated significantly higher objective response rates compared to placebo in controlled studies.
- Oral Administration: Convenient tablet form administered every other day as prescribed by a veterinarian.
- FDA Approved Use: Approved by the U.S. FDA for treatment of recurrent grade II or III mast cell tumors in dogs.
Variants
10 mg Tablets
15 mg Tablets
50 mg Tablets
Ingredients
Active Ingredients
Toceranib phosphate.
How to Use
Recommended-Dosage Chart
|
Dog Body Weight (lb) |
Dog Body Weight (kg) |
Total Dose (mg) |
10 mg Tablets |
15 mg Tablets |
50 mg Tablets |
|
11.0 to 11.8 |
5.0 to 5.3 |
15 mg |
- |
1 |
- |
|
15.3 to 18.5 |
7.0 to 8.4 |
25 mg |
1 |
1 |
- |
|
22.1 to 25.4 |
10.1 to 11.5 |
35 mg |
2 |
1 |
- |
|
28.8 to 32.2 |
13.1 to 14.6 |
45 mg |
- |
3 |
- |
|
32.3 to 35.5 |
14.7 to 16.1 |
50 mg |
- |
- |
1 |
|
45.7 to 50.7 |
20.8 to 23.0 |
70 mg |
- |
2 |
1 |
|
66.0 to 71.2 |
30.0 to 32.3 |
100 mg |
- |
- |
2 |
|
94.9 to 105.0 |
43.1 to 47.6 |
150 mg |
- |
- |
3 |
|
128.9 to 138.9 |
58.5 to 63.0 |
200 mg |
- |
- |
4 |
|
191.7 to 220.5 |
87.0 to 100.0 |
300 mg |
- |
- |
6 |
The initial recommended dosage is 3.25 mg per kg body weight administered orally every other day.
Dosage & Administration Instructions
- Prescription Only: This medication is limited by federal law to being administered by or under the direction of a licensed veterinarian.
- Initial Dose: Administer 3.25 mg per kg body weight orally every other day.
- Dose Adjustments: Reduce dose by 0.5 mg per kg if adverse reactions occur.
- Temporary Interruption: Treatment may be stopped up to two weeks to manage toxicity.
- With Or Without Food: Tablets may be administered with or without food.
- Do Not Split: Tablets must not be split or broken before administration.
Disclaimer: This dosage information is provided by the manufacturer. Always consult your veterinarian before administering or adjusting any supplement for your pet.
Additional Information
Precautions
- Vascular Risk: May cause vascular dysfunction, including edema and thromboembolism, requiring monitoring.
- GI Complications: Serious gastrointestinal ulceration or perforation has occurred rarely in treated dogs.
- Hematologic Monitoring: Neutropenia, anemia, and hypoalbuminemia may require temporary treatment interruption.
- Breeding Contraindication: Do not use in breeding, pregnant, or lactating dogs.
- Young Dogs: Safety not evaluated in dogs under 24 months or under 5 kg.
Possible Side Effects
- Diarrhea: Diarrhea was commonly reported during clinical field studies.
- Vomiting: Vomiting occurred frequently in dogs receiving treatment.
- Loss of Appetite: Decreased appetite or anorexia was commonly observed.
- Lethargy: Reduced activity levels were reported in treated dogs.
- Weight Reduction: Some dogs experienced considerable weight loss during the course of treatment.
- GI Bleeding: Blood in stool and gastrointestinal bleeding were observed in clinical studies.
Storage Information
- Maintain Temperature: Store at a stable room temperature ranging from 20 to 25 degrees Celsius.
- Child Safety: Ensure it is kept away from children and in a safe place.
- Original Packaging: To ensure stability and safety, store the tablets in their original container.
Shipping & Return
We offer ground, express, priority, and international delivery; see our shipping policy for details.
For return instructions or product concerns, please refer to our detailed refund policy.
Prescription items are NON-RETURNABLE and NON-REFUNDABLE.
Frequently Asked Questions
Q1: What is PALLADIA used for in dogs?
Ans: PALLADIA is used to treat recurrent cutaneous mast cell tumors in dogs classified as Patnaik grade II or III, regardless of regional lymph node involvement. It has a FDA approval and can only be prescribed by a licensed veterinarian.
Q2: How does PALLADIA work to treat mast cell tumors?
Ans: PALLADIA is a tyrosine kinase inhibitor that targets certain receptors, such as KIT, VEGFR2, and PDGFR. It functions by directly preventing the growth of tumor cells and decreasing the formation of blood vessels that nourish tumors, assisting in the management of mast cell tumor progression.
Q3: How often should PALLADIA be given to dogs?
Ans: The suggested starting dose is 3.25 mg for each kilogram of body weight, given orally every two days. Adjustments to the dose or short breaks may be necessary depending on side effects and the veterinarian's evaluation during the course of treatment.
Q4: What are the most common side effects of PALLADIA?
Ans: Frequent side effects noted in clinical trials consist of diarrhea, vomiting, reduced appetite, lethargy, lameness, weight reduction, and gastrointestinal bleeding. Treated dogs also exhibited laboratory irregularities such as neutropenia and hypoalbuminemia.
Q5: Is PALLADIA safe for pregnant or breeding dogs?
Ans: PALLADIA should not be used in breeding dogs or in pregnant or lactating females. As an antiangiogenic agent, it may interfere with fetal blood vessel development and could cause harm to an unborn puppy.
